Skip to main content
main-content

12-10-2018 | Multiple sclerosis | Video

ECTRIMS 2018: : ORATORIO extension-phase trial findings show sustained reduction in MS disability progression with ocrelizumab

Jerry Wolinksy summarises his findings from the open-label extension period of the phase III ORATORIO trial looking at sustained disability progression with ocrelizumab in patients with primary progressive multiple sclerosis (8:20).

Funding for this video was provided by F. Hoffmann-La Roche Ltd, Basel, Switzerland.

image credits